To fulfill Neuright’s Mission, Vision, and Promise, we have created a new theragnostic platform (combining therapy and diagnostic functions) that can provide sensitive diagnosis, neuropathy therapy to promote nerve re-growth, and drug delivery. The diagnostic is our minimum viable product (MVP) and is currently under R&D optimization and preclinical validation.
Here is where we are to date, with some milestone achievements and a look to the future:
> By 2023 we expect our product to be ready to be distributed to thought leaders throughout the nation.
> Neuright, Inc. has been awarded a National Science Foundation Small Business Technology Transfer (STTR) Phase 1 award of $225,000. Through this 1 year of funding, the prototype MVP device is being optimized in a pre-clinical model to then move into human.
> With $25,000 from the Maine Top Gun program, we are able to put our minimum viable product into clinical trials.
> Right now we are filing to register our intellectual property and testing our prototype, putting it through preclinical validation. A provisional patent has been submitted.
> We have received more than $350,000 in non-diluted grant funding to date. This funding has allowed us to take our product from the bench, bring it through customer-discovery market research, and create our company.
